Inactive Instrument

Melinta Therapeutics, Inc.

Equities

Biotechnology & Medical Research

Melinta Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 12, 2019 at 05:16 pm EST

Melinta Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 15.870 million compared to USD 34.078 million a year ago. Operating loss was USD 200.181 million compared to USD 26.667 million a year ago. Net loss was USD 213.382 million compared to USD 27.860 million a year ago. Basic loss per share was USD 15.67 compared to USD 2.49 a year ago. For the nine months, total revenue was USD 45.909 million compared to USD 60.941 million a year ago. Operating loss was USD 251.910 million compared to USD 119.991 million a year ago. Net loss was USD 276.094 million compared to USD 113.072 million a year ago. Basic loss per share was USD 22.52 compared to USD 13.3 a year ago.

Latest news about Melinta Therapeutics, Inc.

Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	Feb. 23	CI
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	Feb. 20	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	23-10-02	CI
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	23-07-10	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	23-03-22	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	23-01-25	CI
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	22-11-28	CI
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	22-04-06	CI
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™	21-09-20	CI
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)	21-07-07	CI
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy	21-07-06	CI
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021	21-06-29	CI
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer	21-03-29	CI
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections	21-03-15	CI
Melinta Therapeutics, LLC Appoints Kristen Allgor as Chief Human Resources Officer	20-11-16	CI
Melinta Therapeutics Announces Executive Changes	20-08-03	CI
Melinta Therapeutics Announces CEO Changes	20-08-03	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-23	CI
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	20-05-14	CI
Melinta Therapeutics, Inc. Emerged from Bankruptcy	20-04-20	CI
Second Modified First Amended Reorganization Plan Approved for Melinta Therapeutics, Inc.	20-04-11	CI
First Amended Disclosure Statement Approved for Melinta Therapeutics, Inc.	20-02-25	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Melinta Therapeutics, Inc.	20-02-19	CI
Bidding Procedure Approved for Melinta Therapeutics, Inc.	20-02-11	CI

Chart Melinta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Melinta Therapeutics Inc is a United States-based commercial-stage antibiotics company. The Company's products include Vabomere, Orbactiv, Minocin for injection, and Baxdela. Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Vabomere is indicated for the treatment of patients over 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs). Minocin for injection is indicated for the treatment of infections due to susceptible isolates of designated microorganisms, including Acinetobacter species bacteria.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	114B
REGENERON PHARMACEUTICALS, INC.	+12.01%	107B
BIONTECH SE	-3.07%	22.22B
ARGENX SE	-0.67%	21.28B
GENMAB A/S	-4.64%	18.8B
BEIGENE, LTD.	-6.90%	17.51B
WUXI APPTEC CO., LTD.	-39.36%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.2B

Bio Therapeutic Drugs